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Abstract
Background: The signal transducer and activator of transcription 3 (STAT3) mediates gene
expression in response to numerous growth factors and cytokines, playing an important role in
many cellular processes. To better understand the molecular mechanisms by which Stat3 influences
gene expression in the lung, the effect of pulmonary epithelial cell specific deletion of Stat3 on
genome wide mRNA expression profiling was assessed. Differentially expressed genes were
identified from Affymetrix Murine GeneChips analysis and subjected to gene ontology classification,
promoter analysis, pathway mapping and literature mining.
Results: Total of 791 mRNAs were significantly increased and 314 mRNAs were decreased in
response to the deletion of Stat3Δ/Δ in the lung. STAT is the most enriched cis-elements in the
promoter regions of those differentially expressed genes. Deletion of Stat3  induced genes
influencing protein metabolism, transport, chemotaxis and apoptosis and decreased the expression
of genes mediating lipid synthesis and metabolism. Expression of Srebf1 and 2, genes encoding key
regulators of fatty acid and steroid biosynthesis, was decreased in type II cells from the Stat3Δ/Δ
mice, consistent with the observation that lung surfactant phospholipids content was decreased.
Stat3 influenced both pro- and anti-apoptotic pathways that determine cell death or survival. Akt, a
potential transcriptional target of Stat3, was identified as an important participant in Stat3 mediated
pathways including Jak-Stat signaling, apoptosis, Mapk signaling, cholesterol and fatty acid
biosynthesis.
Conclusion:  Deletion of Stat3  from type II epithelial cells altered the expression of genes
regulating diverse cellular processes, including cell growth, apoptosis and lipid metabolism. Pathway
analysis indicates that STAT3 regulates cellular homeostasis through a complex regulatory network
that likely enhances alveolar epithelial cell survival and surfactant/lipid synthesis, necessary for the
protection of the lung during injury.
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Background
The signal transducers and activators of transcription
(STATs) were initially identified as a family of latent cyto-
plasmic transcription factors that are activated by various
cytokines, growth factors and other stimuli, and phospho-
rylated by many protein kinases [1-4]. In response to var-
ious stimuli, STAT family members are phosphorylated by
receptor associated kinases, form homo- or heterodimers
and are translocated to the cell nucleus where they activate
transcription [5]. Recent studies also support the role of
unphosphorylated STAT3 that accumulates in nucleus
and activates transcription by binding to NFkappaB [6].
STAT3 regulates a variety of biological processes, function-
ing at both transcriptional and non-transcriptional levels
to influence cell growth, survival and metabolism. Its
capacity to induce cell transformation and tumorigenesis
makes it a potential therapeutic target for various cancers
[7,8].
Systemic deletion of Stat3  is embryonic lethal in the
mouse, indicating its important role in embryogenesis [9].
Biological roles of STAT3 in various organs and cells have
been studied in vitro as well as cell specific deletion in the
mouse in vivo. The biological consequences of Stat3 dele-
tion are surprisingly diverse and sometimes contradictory.
For example, cardiomyocyte-specific STAT3 deficiency
caused cardiac fibrosis and heart dysfunction with
advanced age [10]. Hepatic cell specific deletion of Stat3
caused insulin resistance associated with increased expres-
sion of gluconeogenic genes [11]. Conditional ablation of
Stat3  in respiratory epithelium of the mouse (Stat3Δ/Δ
mice) did not alter lung morphogenesis or function but
enhanced susceptibility to hyperoxia and adenoviral
induced lung injury whereas overexpression of Stat3C (a
constitutive active form of STAT3) in pulmonary epithe-
lium protects against hyperoxic lung injury, suggesting
that STAT3 is required for the maintenance of surfactant
homeostasis and lung function during injury [12-14].
While STAT3 has been proposed as an anti-apoptotic pro-
tein through the induction of survival genes such as Bcl2-
like 1(Bcl-X) and B-cell leukemia/lymphoma 2 (Bcl-2),
STAT3 also exerts pro-apoptotic effect through the regula-
tion of insulin-like growth factor binding protein 5
(IGFBP-5) to modulate mammary epithelial apoptosis
[4,15]. STAT3 is abundantly and ubiquitously expressed
in many tissues and distributed between the cell cytosol
and nucleus. A direct effect of non-phosphorylated, cyto-
plasmic STAT3 on cell motility was reported recently
through direct protein-protein interactions [16], indicat-
ing a non-transcriptional function of STAT3.
The functions of STAT3 vary in different cellular and phys-
iologic contexts, influencing diverse gene targets by inter-
action with other proteins and genes. The diversity of
STAT3 functions indicate that STAT3 is involved in com-
plex genetic networks to maintain cellular homeostasis
rather serving a singular role in acute phase responses as
initially defined. In the present study, we sought to sys-
temically study the role of STAT3 in pulmonary epithelial
cell homeostasis. Using knowledge based gene expression
profiling approaches and a conditional system that selec-
tively deleted Stat3 in the respiratory epithelium; we iden-
tified a large STAT3-dependent network that influences a
wide variety of biological processes in type II alveolar cells
in the lung.
Results and Discussion
Identification of differentially expressed genes in alveolar 
type II epithelial cells from Stat3Δ/Δ mice
In previous studies Stat3 mRNA and protein expression
were markedly reduced in Type II cells isolated from
Stat3Δ/Δ mice, being less than 10% of control levels [12].
To identify the RNAs influenced by the conditional dele-
tion of Stat3Δ/Δ, RNAs isolated from alveolar epithelial
type II cells of control and Stat3Δ/Δ mice were compared
using Affymetrix murine genome MOE430 gene chips.
The complete dataset can be found at Gene Expression
Omnibus (GEO) [17]; Accession no. GSE6846. Total of
1105 genes were identified as significantly altered using
the criteria described in Method. Among them, 791
mRNAs were increased and 314 mRNAs were decreased in
response to the deletion of Stat3Δ/Δ in the lung (Additional
file 1). Changes in mRNA expression of a subset of genes
including Malt1, Rnt4, Reg3g, Bcl2l1, Cds2, Cdipt, Fasn,
Acox2, Akt2, Gpam, Foxj1, Abca3, Srebf1, Srebf2 and Scap
were validated by real-time RT-PCR. Genes cross validated
by RT-PCR are listed in Table 1 and indicated by asterisks
(*) in Additional file 1.
Functional classification of differentially expressed genes 
revealed the dysregulation of various biological processes 
in type II epithelial cells from Stat3Δ/Δ mice
Differentially expressed genes were classified according to
Gene Ontology (GO) classification on Biological Process.
The Fisher Exact Test was used to calculate the probability
of each category that was overrepresented in the selected
list using the entire MOE430 mouse genome as reference
dataset. Deletion of Stat3 from type II cells significantly
induced the genes involved in protein metabolism, pro-
tein transport, chemotaxis and apoptosis and decreased
the expression of genes in lipid synthesis and metabolism
(Table 2).
Promoter analysis identified putative common regulators 
of the differentially expressed genes
To identify putative common transcription factors regulat-
ing the type II cell responses to Stat3 deletion, promoter
region (-2kb to exon1) of differentially expressed genes
were searched for overrepresented cis-elements using Mat-
Inspector (Genomatix) vertebrate matrix library. In com-BMC Genomics 2007, 8:455 http://www.biomedcentral.com/1471-2164/8/455
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pare with the sequence of random chosen gene
promoters, the cis-elements significantly enriched in the
promoter region of differentially expressed genes were
selected based on a binomial probability calculation and
their percentage frequency in our selected gene list
(Adjusted p Value < 0.001 and frequency > 50 %). STAT,
EGRF, AHRR, SP1F, ZF5F, E2FF, HIFF, SREB and AP2F
were the most overrepresented cis-elements and may
therefore mediate changes in gene expression in cells from
Stat3Δ/Δ mice (Table 3). The finding that STAT was the
Table 2: Functional Classification of Genes Differentially Expressed in Stat3Δ/Δ mice
GO Classification of Genes Up-regulated in Stat3Δ/Δ mice
Term Count % PValue
Biopolymer modification 115 13.94 7.30E-13
Cellular protein metabolism 164 19.88 5.83E-10
Protein transport 52 6.30 2.49E-07
Phosphate metabolism 62 7.52 3.31E-07
Chemotaxis 17 2.06 1.38E-06
Protein kinase cascade 24 2.91 6.83E-06
Apoptosis 40 4.85 1.69E-05
Regulation of apoptosis 29 3.52 4.93E-05
Positive regulation of cellular metabolism 25 3.03 9.95E-05
Cell migration 19 2.30 2.26E-03
Transcription 106 12.85 2.64E-03
GO Classification of Genes Down-regulated in Stat3Δ/Δ mice
Term Count % PValue
Cellular lipid metabolism 33 9.97 3.60E-13
Lipid biosynthesis 21 6.34 3.59E-11
Sterol metabolism 10 3.02 2.96E-07
Fatty acid metabolism 14 4.23 5.35E-07
Steroid metabolism 12 3.63 6.83E-06
Carboxylic acid metabolism 18 5.44 5.84E-04
Coenzyme metabolism 10 3.02 2.51E-03
Cellular carbohydrate metabolism 12 3.63 3.98E-03
Electron transport 14 4.23 2.64E-02
Phosphate metabolism 21 6.34 3.27E-02
Note: Gene Ontology Analysis was preformed using public available web-based tool DAVID [81]. Overrepresented biological processes were 
selected at the threshold of Fisher Exact Test P-Value ≤ 0.05 and minimum gene counts belonging to an annotation term ≥ 2%.
Table 1: Comparison of mRNAs by RT-PCR and RNA microarray
GENE RT-PCR Microarray P-Value for RT-PCR Gene Name
Malt1 3.5 6.27 < 0.050 Mucosa associated lymphoid tissue lymphoma translocation gene 1
Rtn4 2.7 4.86 < 0.050 reticulon 4
Reg3g -5.5 -6.02 < 0.050 regenerating islet-derived 3 gamma
Bcl2l1 -1.2 -1.54 0.053 Bcl2-like 1
Akt2 -1.5 -1.58 < 0.050 thymoma viral proto-oncogene 2
Abca3 -2.4 -1.59 < 0.050 ATP-binding cassette, sub-family A (ABC1), member 3
Scap -1.4 -1.58 < 0.050 SREBP cleavage activating protein
Srebf1 -1.4 -1.69 < 0.050 sterol regulatory element binding factor 1
Srebf2 -1.3 -1.50 0.080 sterol regulatory element binding factor 2
Cdipt -1.8 -1.54 < 0.001 CDP-diacylglycerol--inositol 3-phosphatidyltransferase
Fasn -1.7 -1.57 < 0.001 fatty acid synthase
Acox2 -1.5 -1.67 < 0.001 acyl-Coenzyme A oxidase 2
Cds2 -2.1 -1.78 < 0.001 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase)
Gpam -1.5 -1.54 < 0.001 glycerol-3-phosphate acyltransferase
Note: Fold change of mRNA in Stat3Δ/Δ mice to control is shown.BMC Genomics 2007, 8:455 http://www.biomedcentral.com/1471-2164/8/455
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most enriched cis-elements indicated the identification of
a sub-group of potential direct transcriptional targets of
Stat3  in lung epithelial cells. Sterol regulatory element
binding factors (Srebf1 and 2, known as important tran-
scriptional regulators of fatty acid and steroid biosynthe-
sis), were significantly decreased in Stat3Δ/Δ mice. The
SREB binding site was overrepresented in differentially
expressed genes indicating that it is a potential regulator
of the lipid metabolism pathways altered in Stat3Δ/Δ mice.
Other significantly enriched TFBS include SP1F and HIFF.
STAT3 and SP1 function cooperatively to activate the C/
EBP promoter, the SP1 site being required for IL-6 induc-
tion and transactivation by STAT3 [18]. HIF1A, SP1,
SMAD3 AND SMAD4 can form multifactor complex, reg-
ulating VEGF and erythropoietin gene transcription
through functional cooperation and association [19-21].
Consistent with the promoter analyses and literature find-
ings, the mRNA expression of Klf5 (a member of the SP1
family) and Hif1a, Smad3 and Smad4 was simultaneously
increased by Stat3 deletion, indicating the potential tran-
scriptional complex formation among the corresponding
transcription factors.
Pathway analysis revealed known and novel functions of 
STAT3 in the lung
Pathway enrichment test is an unbiased way to answer the
question, ''Are the differentially expressed genes enriched
in certain pathways?'' To address this issue, we compared
the overlap of differentially expressed genes in Stat3Δ/Δ
mice with the known biological pathways in KEGG
(Kyoto Encyclopedia of Genes and Genomes) using 1) the
mouse genome and 2) a list of genes shown to be least
changed in response to the Stat3 deletion in the gene array
as background. Results from both analyses were consist-
ent. Jak-Stat Signaling Pathway, Apoptosis, Cytokine-
Cytokine Receptor Interaction, Insulin Signaling Pathway,
Mapk Signaling Pathway, Focal Adhesion, and Wnt Sign-
aling Pathway were among the most enriched pathways
identified from the analysis of differentially expressed
genes (Table 4). mRNAs mediating steroid biosynthesis
and fatty acid metabolism were mostly decreased in
Stat3Δ/Δ mice. The most overrepresented pathways and the
differentially expressed genes associated with those path-
ways are illustrated in Additional files 2. The finding that
known Stat3 functions, including the Jak-Stat Signaling
Pathway were identified from microarray analysis of
Stat3Δ/Δ mice type II cells using knowledge integration
approaches provides support for the utility of the analysis
to detect novel pathways regulated by Stat3.
Stat3 influences protein metabolism in lung type II cells
''Protein metabolism'' was the most enriched biological
process (5.83E-10), accounting for 20% of the induced
genes caused by the deletion of Stat3. More than 40 genes
encoding proteins involved in protein ubiquitination/
ubiquitin cycle were present (Table 5). Of interest, Casitas
B-lineage lymphoma b (Cblb) was increased 7.3 fold.
CBLB is a member of Cbl ubiquitin ligases (E3) protein
family that are tyrosine-phosphorylated in response to a
Table 4: Enriched Pathways In Genes Differentially Expressed in 
Stat3Δ/Δ mice
Term Count % P-Value
Jak-Stat Signaling Pathway 38 3.26 7.56E-09
Apoptosis 24 2.06 5.04E-06
Cytokine-Cytokine Receptor Interaction 43 3.69 2.59E-05
Insulin Signaling Pathway 28 2.40 5.53E-05
Mapk Signaling Pathway 45 3.86 8.51E-05
Focal Adhesion 37 3.17 1.55E-04
Wnt Signaling Pathway 28 2.40 1.68E-04
Overrepresented pathways were identified by comparison the overlap 
of differentially expressed genes and all genes in MOE430 mouse 
genome (reference) with the known KEGG pathways. A pathway is 
considered to be over-represented when a probability P-Value ≤ 0.01 
and gene frequency (genes in the pathway/total number of 
differentially expressed genes) ≥ 2%.
Table 3: Enriched TFBS In Genes Differentially Expressed in Stat3Δ/Δ mice
TFBS Count (Diff_Gene) Frequency 
(Diff_Gene)
Count (background) Frequency 
(background)
P-Value Q-Value
V$STAT 863 0.97 786 0.79 4.93E-59 2.29E-56
V$EGRF 850 0.96 757 0.76 2.92E-57 1.35E-54
V$AHRR 706 0.80 544 0.54 4.04E-53 1.87E-50
V$SP1F 857 0.97 789 0.79 2.15E-49 9.96E-47
V$ZF5F 502 0.57 321 0.32 2.18E-48 1.01E-45
V$E2FF 850 0.96 778 0.78 1.30E-47 6.03E-45
V$HIFF 564 0.64 439 0.44 4.66E-30 2.16E-27
V$SREB 513 0.58 425 0.42 2.76E-17 1.28E-14
V$AP2F 492 0.56 420 0.42 4.93E-15 2.29E-12
Note: promoter sequence (-2000 – 0 bps) from 886 out of 1105 differentially genes were available for analysis. The P-Value is calculated using 
binomial distribution probability. 5 random sets of 1000 mouse gene -2kb promoter regions were used to calculate the background frequency. The 
Q-Value is calculated using single-step Bonferroni adjustment to control for the multiple comparison effect.BMC Genomics 2007, 8:455 http://www.biomedcentral.com/1471-2164/8/455
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wide variety of receptor mediated stimuli, including epi-
dermal growth factor receptors, cytokine receptors such as
colony stimulating factor family receptors (increased 2–3
fold in the Stat3Δ/Δ cells) and immune complex receptors
such as Fcgr2b (increased 2.7 fold). CBLB functions as an
adaptor protein that regulates many signal-transduction
pathways including JAK-STAT signaling pathways through
its ability to interact with critical signaling molecules [22].
The expression of genes encoding known CBLB binding
partners was significantly increased in type II cells from
the Stat3Δ/Δ mice, including SYK kinase (increased 4 fold),
JAK2 (increased 2.1 fold), PKC (increased 2.6 fold), phos-
phatidylinositol 3-kinase (Pik3r1  increased 1.8 fold,
Pik3c2a  increased 3 fold), adenylate cyclase-associated
protein 1 (Cap1 increased 5 fold) and Crk (increased 2.5
fold). These signaling molecules can in turn modulate var-
ious down stream signaling cascades including those
mediated by small G-proteins (multiple members of RAS
oncogene family were induced 2–3 fold), as well as PI3K/
AKT mediated signaling and Nfat induction (increased 4.1
fold) [23-27]. CBLB physically interacts with another
ubiquitin-protein ligase, NEDD4 (increased 3.8 fold), an
interaction that reverses CBLB effects by targeting CBLB
for ubiquitination and proteasomal degradation [28].
SLIM is a known E3 ubiquitin ligase specifically interacts
with activated STAT1 and STAT4, inducing their ubiquiti-
nation and degradation [29]. We speculate that CBLB may
act in a similar manner to regulate STAT3 signaling. In
addition, SUMO1 and SUMO1 specific peptidase 2 were
both increased more than 2 fold in Stat3Δ/Δ mice. SUMO1
can covalently modify many targets including STAT1 and
glucocorticoid receptor NR3C1 (increased 5 fold) and reg-
ulate protein stability and transcriptional activity [30].
Taken together, deletion of STAT3 activates a number of
molecules regulating protein metabolism, stability and
routing, indicating the potential role of ubiquitination
and sumoylation in cytokine signaling and STAT3 activa-
tion that influences cellular adaptation.
STAT3 influences phosphate metabolism and protein 
kinase cascade in lung type II cells
Expression of genes regulating ''Phosphate metabolism''
and ''protein kinase cascade'' were significantly increased
in  Stat3Δ/Δ  mice (3.1E-07 and 1.38E-06, respectively),
accounting for 7.5% of total induced genes (Table 6).
Expression of genes encoding a number of kinase that
Table 5: Genes In Ubiquitin Cycle Were Largely Induced In Stat3Δ/Δ Mice
UniGene ID Fold P-Value Gene Symbol Gene Title
Mm.328206 7.29 9.98E-04 Cblb Casitas B-lineage lymphoma b
Mm.260635 4.56 6.34E-03 Axot Axotrophin
Mm.98668 3.79 6.93E-05 Nedd4l neural precursor cell expressed, developmentally down-regulated gene 4-like
Mm.276229 3.37 1.41E-03 Fbxo30 F-box protein 30
Mm.258476 3.30 6.58E-03 Tbl1x transducin (beta)-like 1 X-linked
Mm.28017 3.22 3.62E-03 Fbxw11 F-box and WD-40 domain protein 11
Mm.16974 3.03 1.66E-04 Usp47 ubiquitin specific peptidase 47
Mm.388965 3.01 8.38E-04 Rnf12 Ring finger protein 12
Mm.41711 2.87 1.43E-03 Pja2 Praja 2, RING-H2 motif containing (Pja2), transcript variant 2, mRNA
Mm.214746 2.75 1.78E-03 Fbxl3 F-box and leucine-rich repeat protein 3
Mm.242646 2.75 1.83E-03 Usp9x ubiquitin specific protease 9, X chromosome
Mm.9002 2.70 6.26E-04 Ube3a ubiquitin protein ligase E3A
Mm.30051 2.53 4.86E-04 Rnf10 Ring finger protein 10
Mm.362118 2.41 9.26E-04 Sumo1 SMT3 suppressor of mif two 3 homolog 1 (yeast) (Sumo1)
Mm.328135 2.36 3.35E-04 Rfwd2 Constitutive photomorphogenic protein (Cop1)
Mm.290908 2.34 3.27E-04 Birc6 baculoviral IAP repeat-containing 6
Mm.180052 2.34 4.84E-03 Ube2d2 Ubiquitin-conjugating enzyme E2D 2
Mm.391601 2.29 9.75E-03 Ube2d3 ubiquitin-conjugating enzyme E2D 3
Mm.4480 2.25 1.28E-03 Rbbp6 Retinoblastoma binding protein 6 (Rbbp6)
Mm.319512 2.24 5.65E-03 Hip2 huntingtin interacting protein 2
Mm.12665 2.19 1.60E-02 Cul3 cullin 3
Mm.244179 2.12 3.75E-03 Herc1 Hect (homologous to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 
(CHC1)-like domain (RLD) 1
Mm.392272 2.10 4.55E-04 Smurf2 SMAD specific E3 ubiquitin protein ligase 2
Mm.297431 1.95 2.84E-03 Senp2 SUMO/sentrin specific peptidase 2
Mm.253542 1.94 1.53E-02 Rnf138 ring finger protein 138
Mm.235407 1.94 1.32E-02 Ube2v2 ubiquitin-conjugating enzyme E2 variant 2
Mm.392862 1.93 3.54E-03 Arih1 ariadne ubiquitin-conjugating enzyme E2 binding protein homolog
Mm.78312 1.89 1.07E-02 Wwp1 WW domain containing E3 ubiquitin protein ligase 1
Mm.44876 1.84 3.88E-03 Trim2 tripartite motif protein 2BMC Genomics 2007, 8:455 http://www.biomedcentral.com/1471-2164/8/455
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phosphorylate STAT3 in vivo or in vitro were increased
[31-35], including Janus kinase 1 and 2 (increased 3.1 and
2.6 fold, respectively), ribosomal protein S6 kinase
polypeptide 3 (Rps6ka3, increased 3.1 fold), met proto-
oncogene (Met, increased 4.2 fold), mitogen activated
protein kinase 8 (Mapk8, increased 4.7 fold) and Dual-
specificity tyrosine-phosphorylation regulated kinase 1a
(Dyrk1a, increased 2.6 fold). The increased expression of
these genes indicates a potential compensatory mecha-
nism related to the lack of activation of STAT3 or its tar-
gets.
STAT3 influences lipid homeostasis in lung type II cells
Expression of genes encoding sterol regulatory element
binding factor 1 and 2 (Srebf1 and Srebf2), their cleavage
activating protein (Scap) and multiple SREBP target genes
involved in lipid metabolism were decreased in Stat3Δ/Δ
mice type II cells. As depicted in Figure 1, genes dedicated
to the biosynthesis of fatty acid, phospholipid and choles-
Table 6: Genes In Phosphate Metabolism Were Largely Induced In Stat3Δ/Δ Mice
UniGene ID Fold P-Value Gene Symbol Gene Title
Mm.188734 8.32 3.47E-05 Adk Adenosine kinase
Mm.21495 4.70 1.82E-03 Mapk8 Mitogen activated protein kinase 8
Mm.3879 4.69 4.29E-05 Hif1a Hypoxia inducible factor 1, alpha subunit
Mm.86844 4.18 1.89E-03 Met Met proto-oncogene
Mm.225505 4.09 2.32E-03 Chka Choline kinase alpha
Mm.375031 4.02 1.39E-03 Syk Spleen tyrosine kinase
Mm.327591 3.60 1.26E-03 Cask Calcium/calmodulin-dependent serine protein kinase
Mm.248647 3.42 2.36E-02 Pi4k2b Phosphatidylinositol 4-kinase type 2 beta
Mm.255822 3.31 2.08E-04 Camk2d Calcium/calmodulin-dependent protein kinase II, delta
Mm.25559 3.30 7.41E-03 Stk17b Serine/threonine kinase 17b (apoptosis-inducing)
Mm.328476 3.15 1.45E-02 Rps6ka3 Ribosomal protein S6 kinase polypeptide 3
Mm.289657 3.14 1.66E-04 Jak1 Janus kinase 1
Mm.3810 3.08 7.64E-03 Pik3c2a Phosphatidylinositol 3-kinase, C2 domain
Mm.202606 3.04 1.02E-04 Mast4 Microtubule associated serine/threonine kinase family member 4
Mm.309867 2.88 3.93E-04 Ptk9 Protein tyrosine kinase 9
Mm.280125 2.86 3.15E-03 Crk v-crk sarcoma virus CT10 oncogene homolog (avian)
Mm.272548 2.82 4.37E-04 Etnk1 Ethanolamine kinase 1
Mm.197552 2.74 1.10E-03 Tgfbr1 Transforming growth factor, beta receptor I
Mm.262330 2.66 1.54E-02 Stk3 Serine/threonine kinase 3 (Ste20, yeast homolog)
Mm.295263 2.65 1.43E-03 Dcamkl1 Double cortin and calcium/calmodulin-dependent protein kinase-like 1
Mm.222178 2.57 2.58E-04 Prkca Protein kinase C, alpha (Prkca), mRNA
Mm.310973 2.56 5.12E-04 Dyrk1a Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1a
Mm.313594 2.50 5.58E-03 Mpp5 Palmitoylated 5 (MAGUK p55 subfamily member 5)
Mm.6710 2.49 3.65E-02 Rock1 Rho-associated coiled-coil forming kinase 1
Mm.440470 2.46 3.16E-03 Crk7 CDC2-related kinase 7
Mm.389061 2.36 1.34E-03 Pftk1 PFTAIRE protein kinase 1 (Pftk1), mRNA
Mm.244236 2.34 8.50E-03 Pkn2 Protein kinase N2
Mm.288141 2.25 7.64E-03 Rp2h Retinitis pigmentosa 2 homolog (human)
Mm.31672 2.21 4.65E-04 Cdk6 Cyclin-dependent kinase 6 (Cdk6), mRNA
Mm.215171 2.20 5.62E-04 Trpm6 Transient receptor potential cation channel, subfamily M, member 6
Mm.3994 2.18 3.98E-04 Dusp16 Dual specificity phosphatase 16
Mm.136511 2.17 5.10E-04 Tlk1 MKIAA0137 protein
Mm.332231 2.16 3.01E-03 Magi2 Membrane associated guanylate kinase, WW and PDZ domain containing 2
Mm.16340 2.13 1.50E-02 Fgfr2 Fibroblast growth factor receptor 2
Mm.275839 2.13 1.00E-02 Jak2 Janus kinase 2
Mm.393114 2.08 7.62E-04 Csnk1a1 Casein kinase 1, alpha 1
Mm.17918 2.08 7.94E-04 Marcksl1 MARCKS-like 1
Mm.368668 2.06 6.49E-04 Csnk1g3 Casein kinase 1, gamma 3 (Csnk1g3), mRNA
Mm.291936 2.01 8.02E-03 Map4k5 Mitogen-activated protein kinase kinase kinase kinase 5
Mm.35290 -2.00 1.42E-02 Ripk4 Receptor-interacting serine-threonine kinase 4
Mm.36006 -2.39 1.22E-03 Ak7 Adenylate kinase 7
Mm.306163 -2.68 8.63E-03 Prkar1b Protein kinase, cAMP dependent regulatory, type I beta
Mm.7373 -2.71 1.05E-03 Per1 Period homolog 1 (Drosophila)
Mm.32831 -2.96 2.47E-02 Wif1 Wnt inhibitory factor 1
Mm.44442 -3.76 2.45E-04 Kndc1 Kinase non-catalytic C-lobe domain (KIND) containing 1BMC Genomics 2007, 8:455 http://www.biomedcentral.com/1471-2164/8/455
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Genes involved in lipids biosynthesis and clearance pathways were altered in type II cells from Stat3Δ/Δ mice Figure 1
Genes involved in lipids biosynthesis and clearance pathways were altered in type II cells from Stat3Δ/Δ mice. A. 
Srebf1 and Srebf2 regulate genes encoding the major metabolic enzymes in the fatty acid, cholesterol and phospholipids biosyn-
thesis. The arrow (↑) indicates that the mRNA level was induced in Stat3Δ/Δ mice; (↓) indicates the mRNA level was reduced in 
Stat3Δ/Δ mice. Gene symbols, descriptions and the expression changes are listed in panel B.BMC Genomics 2007, 8:455 http://www.biomedcentral.com/1471-2164/8/455
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terol were down regulated, with the exception of 3-
hydroxy-3-methylglutaryl-Coenzyme A synthase (Hmgcs),
which was increased. HMGCS participates in other meta-
bolic pathways, including valine, leucine and isoleucine
degradation (KEGG 00280). This analysis indicates that
metabolic pathways regulating fatty acid, phospholipid,
and cholesterol biosynthesis were coordinately decreased
after deletion of Stat3  in type II cells, supporting an
important role of STAT3 in regulating lipids biosynthesis
in the lung. LDL receptor (Ldlr), mediating cholesterol
uptake, and ATP-binding cassette A3 (Abca3), important
for phospholipid transport, lamellar body formation and
pulmonary surfactant secretion in alveolar type II cells
were decreased in the Stat3Δ/Δ mice cells [36-38]. Recent in
vitro studies from our group confirmed the direct binding
of SREBP1c to the Abca3 promoter (Besnard et.al, submit-
ted for publication). On the other hand, the increased
expression of Abca1, a key facilitator of cellular cholesterol
and phospholipid export [39,40] and high density lipo-
protein binding protein (Hdlbp), which may function in
the removal of excess cellular cholesterol, suggests that
cholesterol and phospholipid clearance were induced
after deletion of Stat3. Adenosine kinase (Adk), was
increased 8.2 fold. Cellular role of ADK in lipid metabo-
lism is somewhat controversial [41], Adk deficient mice
developed neonatal hepatic steatosis and die within 14
days with fatty liver [42]. Increased expression of lipid
export genes and decreased expression of genes mediating
lipid biosynthesis likely cause a reduction of total lipids
level in the type II cells of Stat3Δ/Δ mice.
Previous studies demonstrated the susceptibility of Stat3Δ/
Δ mice to lung injury and death related to surfactant dys-
function [12]. Consistent with our prediction from the
present mRNA microarray analysis, the saturated phos-
phatidycholine (SatPC) content in bronchoalveolar lav-
age fluid was significantly decreased in Stat3Δ/Δ  mice
(Figure 2). Significantly decreased SatPC synthesis and
abnormalities in lamellar body numbers and morphology
were also observed in Stat3Δ/Δ mice (data not shown).
Taken together, a number of genes regulating surfactant
lipid homeostasis were altered in type II cells isolated
from the Stat3Δ/Δ mice, consistent with biochemical, func-
tional, and morphologic changes in the surfactant system
that is exacerbated by oxidant stress [12] or expose to
pathogens [13].
Role of Akt in Stat3 regulated lipid metabolism
Our observations support the view that the decrease in
SREBP, at least in part, results in decreased expression of
genes regulating lipid biosynthesis and metabolism in
type II cells from Stat3Δ/Δ mice. SREBPs are master regula-
tors of lipid metabolism. The transcriptional targets, and
the pathways mediated by SREBP in liver have been well
studied [43]. SREBPs are expressed in the developing lung,
SREB1c increases in the developing lung concomitantly
with the perinatal increase in surfactant and lipid synthe-
sis, surfactant protein and Abca3 expression, genes critical
for surfactant function.
However, the role of Stat3 in regulating SREBP and asso-
ciated lipid metabolism in the lung is largely unknown. In
the present analysis, we sought to identify mechanisms by
which Stat3 regulates SREBPs and associated lipid biosyn-
thesis pathways in alveolar type II cells in the lung. The
regulation of SREBPs occurs at both transcriptional and
post-transcriptional levels. The post-transcriptional regu-
lation requires SCAP. Cre-mediated disruption of Scap sig-
nificantly reduced Srebf1 and 2 levels as well as SREBP
target gene expression in liver [44]. There are multiple
potential STAT sites on the Scap  promoter. Thus, Stat3
may influence lipid biosynthesis through the transcrip-
tional regulation of Scap. At transcriptional level, nuclear
hormone receptors (Nr1h2 and Nr1h3) and Pgc1-alpha
and beta are known to regulate SREBPs expression in liver.
Increased expression of Srebf1 and Fasn was associated
with increased hepatic triglyceride content in Stat3 defi-
cient mice [10,45]. In the present study, expression of
SREBP and their down stream targets were decreased in
type II cells from Stat3Δ/Δ mice (a finding that contrast
Surfactant saturated phosphatidylcholine (SatPC) Figure 2
Surfactant saturated phosphatidylcholine (SatPC) 
was significantly decreased in bronchoalveolar lavage fluid 
from the Stat3Δ/Δ mice, n = 8 per group. Aliquots of BALF 
were extracted with chloroform/methanol (2:1) and SatPC 
was isolated with osmium tetroxide followed by measure-
ment of phosphorus as described previously [12]. Statistical 
differences were analyzed by Student t-test.BMC Genomics 2007, 8:455 http://www.biomedcentral.com/1471-2164/8/455
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with the findings in the liver) without changes in other
known regulators such as Nr1h2, Nr1h3, Pgc1-alpha  or
Pgc1-beta, indicating the likely presence of alternative reg-
ulatory mechanisms in lung cells.
We hypothesize that AKT plays an important role in Stat3
regulated SREBP expression and associated lipogenesis in
lung based on the following observations: 1) Protein and
mRNA levels of Akt were increased in cells constitutively
expressing active Stat3 and were reduced after Stat3 deple-
tion [46]. STAT3 binds to Akt1 promoter was confirmed
by ChIP assay [47], suggesting that A kt maybe a direct
transcriptional target of Stat3. AKT, on the other hand,
inhibits  Stat3  transcriptional activity and phosphoryla-
tion [48]. Decreased Akt gene expression seen after dele-
tion of Stat3  may represent a direct effect of Stat3
deficiency or to a negative regulatory response to STAT3
deficiency, 2) AKT activation induces both Srebf1  and
Srebf2 mRNAs and proteins as well as key enzymes in the
cholesterol, fatty acid and membrane lipid biosynthesis
pathways [49], 3) Multiple lines of evidence suggest that
PI3K influences Stat3 activation. STAT3 binds directly to
the PI3K regulatory subunits [50-52]. The expression of
genes encoding for several PI3K subunits were altered
after deletion of Stat3 (see Additional file 1), supporting
the involvement of PI3K/Akt signaling in Stat3 regulated
bioprocesses in lung, and 4) Since AKT physically interacts
with FOXA2 and regulates FOXA2-dependent transcrip-
tional activity [53], the effects of AKT may be mediated, in
part, via Foxa2. Foxa2 expression was reduced more than 2
fold in cells from the Stat3Δ/Δ mice. FOXA2 regulates lipid
metabolism in both lung and liver [54,55]. Deletion of
either Stat3 or Foxa2 resulting in decreased expression of a
number of the overlapping genes that play important
roles in surfactant homeostasis including Abca3 [55].
Thus, interactions between AKT and FOXA2 represent
another potential mechanism by which lipid metabolism
is influenced in Stat3Δ/Δ mice.
Stat3 influences expression of genes mediating apoptosis 
and cell survival
Many genes modulating apoptosis/cell survival were
altered in response to the deletion of Stat3 from type II
cells, including multiple Bcl-2 family members (Bcl2,
Bcl2l1, Mcl1, Bcl2l11 and Bad), caspase 3 (Casp3), FADD-
like apoptosis regulator (Cflar, also known as Flip),
mucosa associated lymphoid tissue lymphoma transloca-
tion gene 1 (Malt1), prostaglandin-endoperoxide syn-
thase 2 (Ptgs2) and nuclear receptor subfamily 3, group C,
member 1 (glucocorticoid receptor, Nr3c1). In depth liter-
ature mining identified more apoptosis related genes than
did analysis by Gene Ontology annotation. As depicted in
Figure 3, our study indicates that STAT3 regulates apopto-
sis in a complex manner via processes that occur in multi-
ple intracellular locations. Thus, STAT3 appears to serve as
key regulator of apoptosis in alveolar type II cells. Among
those apoptosis related genes, Malt1, Ptgs2 and  Nr3c1
were strongly induced (> 5 fold in compare with control).
MALT1 interacts with BCL10 (increased 2 fold in Stat3Δ/Δ
mice). The formation of this complex is essential for NF-
kappaB activation that, in turn, play a role in cell survival.
IKKB phosphorylates BCL10 in its MALT1 interaction
domain, causing BCL10 and MALT1 to disassociate,
resulting in attenuation of NFKB signaling and cytokine
production [56,57]. PTGS2 also known as COX-2, a key
enzyme in prostaglandin biosynthesis, that is highly
expressed in alveolar type II cells. The expression of Ptgs2
is increased in epithelial tumors, including non-small cell
lung and prostate cancers via activation of the IL-6/
GP130/STAT3  signaling pathway [58]. This pathway
could contribute to tumor formation by promotion of
tumor cell resistance to apoptosis via inhibitor of apopto-
sis (IAP)-dependent mechanism [58,59]. Consistent with
these observations, Ptgs2, Il6st and two of the IAP family
members (Birc4 and Birc6) were correspondingly induced
in Stat3Δ/Δ cells (5.7, 1.7, 3.2 and 2.3 fold respectively).
Nr3c1 (increased 5.1 fold) encodes a receptor for gluco-
corticoids that can act as both a transcription factor and as
a regulator of other transcription factors. STAT3 and
NR3C1 physically interact to mediate effect of glucocorti-
coid on the IL-6-mediated inflammatory response [60-
62]. NR3C1 also interacts with stress-responsive transcrip-
tion factors (Hif1a, increased 4.7 fold), mitogen activated
protein kinase 8 (Mapk8 or Jnk, increased 4.7 fold) and
tyrosine 3-monooxygenase/tryptophan 5-monooxygen-
ase activation protein, epsilon polypeptide (Ywhal,
increased 3.3 fold), a 14-3-3 family of proteins implicated
in the pathogenesis of small cell lung cancer [63,64].
STAT3 is likely to regulate apoptosis by multiple mecha-
nisms including gene transcription. Bcl-xL is the direct
transcription target of STAT3[65]. STAT3 can serve as an
anti-apoptotic factor by transcriptional up-regulating the
expression of Bcl-xL [66]. The decrease of Bcl-xL may rep-
resent a direct response to Stat3 deletion. The fact that
expression of Bcl-xL blocked the apoptotic effects of the
adenovirus in lung injury suggested that Bcl-xL may medi-
ate the role of STAT3 in the regulation and survival of the
respiratory epithelium [13]. The Pi3k-Akt pathway repre-
sents a second mechanism by which STAT3 influences
cytoprotection. Pi3k-Akt signaling mediates a wide range
of down stream targets to regulate apoptosis [67]. For
example, AKT phosphorylates multiple Bcl-2 family mem-
bers, including BAD and Bcl-xL [68], inhibits caspase 3
activation [66] and blocks cytochrome C release from
mitochondria [69]. Another mechanism by which STAT3
modulates apoptosis is through protein-protein interac-
tions. Bcl-xL is a direct transcriptional target of STAT3; Bcl-
xL interacts with VDAC1 to regulate the outer mitochon-
drial membrane channel induce apoptosis [70,71].BMC Genomics 2007, 8:455 http://www.biomedcentral.com/1471-2164/8/455
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CASP3 can interact with multiple apoptosis proteins
including CFLAR, BIRC4 and 6, BCL2 and APP [72-75].
The expression of Casp3 as well as its interaction partners
was induced in Stat3Δ/Δ mice. NR3C1 has both pro- and
anti-apoptotic effects. NR3C1 physically interact with
STAT3, HIF1A, MAPK8, YWHAL [63,64,76]; these stress-
responsive transcription factors and signaling molecules
were largely induced in the present array from Stat3Δ/Δ
type II alveolar epithelial cells. The close transcriptional
communication and physical interactions among these
transcriptional regulators likely play a critical role in regu-
lating the balance of apoptosis and cell survival. In the
present study, effects of STAT3 deletion were assessed in
type II epithelial cells purified from the adult mouse lung.
mRNA was isolated immediately after isolation to avoid
cell culture dependent alteration in gene expression. It is
possible that the cells have undergone added cellular
stress during protease treatment, isolation and purifica-
tion, which in turn may influence the expression of genes.
Our results support the view that STAT3 regulates the bal-
ance between a subset of pro- and anti-apoptotic genes,
determining the cell death or survival through multiple
mechanisms. Consistent with the present microarray pre-
diction, cleaved caspase-3 and TUNEL positive cells were
Genes involved in apoptotic pathways were altered in type II cells isolated from Stat3Δ/Δ mice Figure 3
Genes involved in apoptotic pathways were altered in type II cells isolated from Stat3Δ/Δ mice. Genes associated 
with apoptosis were identified via literature mining using Pathway Studio 4.0 (Ariadne Genomics, Inc.). STAT3 regulates apop-
tosis positively and negatively, via processes occurring in multiple intracellular compartments. Genes up-regulated in Stat3Δ/Δ 
mice are framed in red. Genes down-regulated in Stat3Δ/Δ mice are framed in green. Each dashed line demarcated with a larger 
dot linking "apoptosis" and each gene node indicates a regulatory relationship based on the literature references. Regulatory 
relationships are denoted by line colors (green, positive  regulation; red, negative regulation; and gray, regulation direction is  
unknown).BMC Genomics 2007, 8:455 http://www.biomedcentral.com/1471-2164/8/455
Page 11 of 15
(page number not for citation purposes)
significantly increased in Stat3Δ/Δ mice following adenovi-
ral infection and the apoptosis can be blocked by expres-
sion of Bcl-xL [13].
Conclusion
Our previous studies demonstrated that Stat3 plays criti-
cal role in cyto-protection during lung injury [12,13].
Present data support the role of Stat3 in enhancing epithe-
lial cell survival and surfactant lipid synthesis that contrib-
ute to the maintenance of lung function. Deletion of Stat3
from type II alveolar epithelial cells induced the expres-
sion of the genes regulating protein metabolism, protein
transport, chemotaxis and apoptosis while decreasing the
expression of genes regulating lipid synthesis and metab-
olism. Critical to pulmonary function during injury, Stat3
influences the expression of genes regulating surfactant
lipid synthesis and surfactant homeostasis including
Abca3. As illustrated in Figure 4, the present study identi-
fied a complex regulatory network by which Stat3 regu-
lates gene expression in type II alveolar cells that is
required for cellular homeostasis following injury. STAT3
likely interacts with AKT/FOXA2 in the regulation a
number of biological processes in alveolar type II cells,
including cell survival/apoptosis, cholesterol and fatty
acid biosynthesis required for surfactant homeostasis and
lung function.
Methods
Transgenic Mice
SP-C-rtTA/(tetO)7CMV-Cre/Stat3flx/flx  triple-transgenic
mice were generated as described previously [12]. Stat3flx/
flx mice were a kind gift of Dr. Takeda (Hyogo College of
Medicine, Japan) [8]. In the presence of doxycycline, exon
21 of the Stat3 gene is permanently deleted from respira-
tory epithelial cells prior to birth (Stat3Δ/Δ mice) [12].
Stat3 deleted transgenic (Stat3Δ/Δ) and non-deleted litter-
Schematic representation of the proposed role of Stat3 in cytoprotection of the lung in normal (A) versus Stat3Δ/Δ mice (B) Figure 4
Schematic representation of the proposed role of Stat3 in cytoprotection of the lung in normal (A) versus 
Stat3Δ/Δ mice (B). Stat3 plays critical role in cyto-protection during lung injury [12, 13]. Present data support the role of Stat3 
in enhancing epithelial cell survival and surfactant lipid synthesis that contribute to the maintenance of lung function. For sim-
plicity, only representative genes were included.BMC Genomics 2007, 8:455 http://www.biomedcentral.com/1471-2164/8/455
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mates (double transgenic,SP-C-rtTA, or tetO7CMV-Cre
and Stat3flx/flx) were used for the experiments. Doxycycline
was administered to the dams in the food at a concentra-
tion of 625 mg/kg (Harlan Teklad, Madison, WI) from
embryonic day 0 (E0) to postnatal day 25 (P25), resulting
in extensive deletion of Stat3 in respiratory epithelial cells
[12]. As previously described, deletion of Stat3 did not
alter lung size, morphology or survival under non-stressed
condition [13].
RNA Extraction
Alveolar type II cells were isolated from 8 weeks old, sex
and age matched littermate control and Stat3Δ/Δ  mice
using collagenase and differential plating as described by
Rice et al.[77]. Type II cells from 3 mice were pooled to
obtain one cell pellet. Three independent pools were gen-
erated from control and Stat3Δ/Δ mice separately for puri-
fication of RNA and microarray hybridization. Type II
cells were homogenized with TRIzol reagent (Invitrogen,
Carlsbad, CA). RNA concentration was measured by spec-
trophotometer and normalized prior to cDNA synthesis.
These cell isolates consist of more than 90% alveolar type
II cells with residual alveolar macrophages as the major
contaminating cell. Purity was assessed by modified
Papanicolaou stain. Purity and number of type II cells iso-
lated from Stat3Δ/Δ mice were not different from controls.
RNA Microarray Analysis
mRNA was extracted from three independent pools of iso-
lated type II cells from adult Stat3Δ/Δ and control mice. The
cRNA was then hybridized to the murine genome
MOE430 (consists of ≈ 45000 gene entries) chips
(Affymetrix, Santa Clara, CA) according to the manufac-
turer's protocol. The RNA quality and quantity assess-
ment, probe preparation, labeling, hybridization and
image scan were carried out in the CCHMC Affymetrix
Core using standard procedure. RNA quality and quantity
were analyzed by spectrophotometer. The A260/A280
ratio was used to determine RNA purity with the accepta-
ble region of 1.9–2.1. Affymetrix Microarray Suite 5.0 was
used to scan and quantitate the gene chips under default
scan settings. Normalization was performed using the
Robust Multichip Average model [78,79]. Data were fur-
ther analyzed using affylmGUI from R/Bioconductor
package [80]. Differentially expressed genes were selected
with the threshold of T-Test P-value ≤ 0.05, False Discov-
ery Rate (FDR) ≤ 10% and fold change ≥ 1.5. We priori-
tized the mRNAs whose abundance consistently changed
in multiple probe sets by selecting them without the FDR
consideration. Unknown cDNA clones/ESTs and dupli-
cated gene entries were removed from further functional
analysis.
Gene Ontology Analysis
Gene Ontology Analysis was performed using public
available web-based tool David (database for annotation,
visualization, and integrated discovery) [81]. Overrepre-
sented biological processes were selected at the threshold
of Fisher Exact Test P-Value ≤ 0.05 and minimum gene
counts belonging to an annotation term ≥ 2%.
Promoter Analysis: Transcription Factor Binding Sites 
Search
Promoter sequences of all differentially expressed genes (-
2000 bp upstream from the tentative TSS) were retrieved
from our database (originally downloaded from UCSC
Genome browser) and searched for over-represented TFBS
(Transcription Factor Binding Site) in these sequences
using MatInspector (Genomatix) using the complete Ver-
tebrate Matrix Library 6.2. The P value is calculated using
binomial distribution probability by comparing the
matrix match of the promoter regions of differentially
expressed genes with the promoters from random mouse
genes sets (-2kb for all the promoters). The single-step
Bonferroni adjustment is used to control for the multiple
comparison effect (i.e., multiplication of p-value by the
number of TFBS in Genomatix Vertebrate Matrix Library).
Pathway Enrichment Test
Overrepresented pathways were identified by comparison
the overlap of differentially expressed genes and all genes
in MOE430 mouse genome (reference) with the known
KEGG pathways. A Fisher's exact test for 2·2 contingency
table was used to calculate the statistical significance. A
pathway is considered to be over-represented when a
probability P value = 0.01 and gene frequency (genes in
the pathway/total number of differentially expressed
genes) ≥ 2%.
Literature Mining
Potential protein-protein or protein-DNA interactions
were identified using Pathway Studio (Ariadne Genom-
ics) that contains MedScan, an automated text-mining
tool to search the entire PubMed and other public sources
(The current version database contains more than 15 mil-
lion Medline abstracts/full text). Gene expression profil-
ing results was imported into the Studio and used to
interpret pathways, gene regulation networks, and protein
interaction maps.
Validation of mRNAs
Real-time RT-PCR was used to cross validate changes in a
subset of genes from microarray selection. mRNA was
extracted from alveolar type II epithelial cells isolated
from Stat3Δ/Δ and control mice using RNeasy Protect mini
kit (Qiagen, Valencia, CA) according to the manufac-
turer's protocol. RNA concentration was measured by
spectrophotometer. cDNA was made with SuperScriptBMC Genomics 2007, 8:455 http://www.biomedcentral.com/1471-2164/8/455
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First-Strand Synthesis System (Invitrogen, Carlsbad, CA).
Malt1, Rtn4, Reg3g, Bcl2l1, Abca3, Scap, Fasn, Srebf1 and
Srebf2  were detected using primers listed Changes in
mRNA were determined in type II cells isolated from
Stat3Δ/Δ  and controls (n  = 3–4/group). The following
primers were used: Malt1: forward, TAT CCA GGA GGA
CCC CAT GT and reverse, TCT GAT CAA AGC CAG TTA
GCA TCAT; Rtn4: forward, AAG TGG AAG GAG TTT GAG
AGA GCA and reverse, CTG TCT CAA AGC AGA TGT GAA
AGC; Reg3g: forward, TGC CAA AAG AGC CCT CAG GA
and reverse, TGC CTG AGG AAG AGG AAG GAT TCG;
Bcl2l1: forward, TCT CTC TCC TCT GTC CAC CCT TG and
reverse, TGC CCC TCA GAA GCC AGA AC; Abca3: for-
ward, GCA TTG CCC TCA TTG GAG AGC CTG and
reverse, TCC GGC CAT CCT CAG TGG TGG G; Scap: for-
ward, TGA CCA CAA ACA AGG AGA GC and reverse, CAG
GAA CAC CAA ACA GCA AG; Srebf1: forward, AAG CCG
GGT GGG CGC CGG CGC CAT and reverse, GTC GTT
CAA AAC CGC TGT GTC CAG; Srebf2: forward, CAT CCA
GCA GCC TTT GAT ATA CCA G and reverse, AGG ACC
GGG ACC TGC TGC ACC TGT G. Fasn: forward, GGA CAT
GGT CAC AGA CGA TGA C and reverse, GTC GAA CTT
GGA CAG ATC CTT CA. The PCR product was separated
by the 1% agarose gel electrophoresis. β-actin was used as
the internal control. Taqman Gene Expression Assay were
used to confirm the expression of Akt2, Cdipt, Acox2, Cds2
and Gpam using Applied Biosystems 7300 Real-Time PCR
System and company designed probes (Applied Biosys-
tems). Statistical differences were determined using
unpaired Student's t-tests.
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